Predicting poor outcome in patients with suspected COVID-19 presenting to the Emergency Department (COVERED) - Development, internal and external validation of a prediction model

Autor: Kaoutar Azijli, Giuseppe Natalini, Sfb van der Horst, J Heijmans, T de Rooij, P. M. van de Ven, Pwb Nanayakkara, P Terragnoli, M W Heijmans, Ejg Peters, M. Abu Hilal, Awe Lieveld, N. de Graaf, Ruud S. Kootte

Publikováno v: Azijli, K, Lieveld, A, van der Horst, S, de Graaf, N, Kootte, R S, Heijmans, M W, van de Ven, P M, Peters, E, Heijmans, J, Terragnoli, P, Natalini, G, Abu Hilal, M, de Rooij, T & Nanayakkara, P 2021, ' Predicting poor outcome in patients with suspected COVID-19 presenting to the Emergency Department (COVERED)-Development, internal and external validation of a prediction model ', Acute Medicine, vol. 20, no. 1, pp. 4-14 .
Scopus-Elsevier
Acute Medicine, 20(1), 4-14. Rila Publications Ltd

BACKGROUND: A recent systematic review recommends against the use of any of the current COVID-19 prediction models in clinical practice. To enable clinicians to appropriately profile and treat suspected COVID-19 patients at the emergency department (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8ef48d1bc1fc4b013c879d70cec998
https://research.vumc.nl/en/publications/4b9fe365-0ba5-42cf-bcda-66594c8ccb1f

Resistance Profile of Bacteria Isolated from Diabetic Wounds: Phytochemicals and Antibacterial Studies of Eriosema robustum Leaf Extracts.

Autor: Tsaffo, Gael Marius¹, Djenguemtar, Josias^1,2, Chegaing Fodouop, Siméon Pierre³, Merzouk, Hafida⁴, Sokoudjou, Jean Baptiste^1,4, Kamsu, Gabriel Tchuente^1,5, Laure Feudjio, Huguette Bocanestine¹, Kodjio, Norbert¹, Mebarki, Abdelouahab⁴, Gatsing, Donatien¹ gatsingd@yahoo.com

Publikováno v: Trends in Sciences. Jun2024, Vol. 21 Issue 6, p1-17. 17p.

Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.

Autor: Tusch E; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Ryom L; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Pelchen-Matthews A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom., Mocroft A; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom., Elbirt D; Allergy, Immunology and HIV Unit, Kaplan Medical Center, Rehovot, Israel., Oprea C; HIV department, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania., Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland., Staehelin C; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland., Zangerle R; Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruck, Innsbruck, Austria., Suarez I; Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany., Vehreschild JJ; Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany., Wit F; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands., Menozzi M; Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy., d'Arminio Monforte A; Italian Cohort Naive Antiretrovirals (ICONA), ASST Santi Paolo e Carlo, Milano, Italy., Spagnuolo V; Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy., Pradier C; Nice HIV Cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France., Carlander C; Swedish InfCare HIV Cohort, Karolinska University Hospital, Stockholm, Sweden., Suanzes P; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Wasmuth JC; Infectious Diseases/HIV Department of the Medical Clinic I, University Hospital Bonn, Bonn, Germany., Carr A; HIV and Immunology Unit, St Vincent's Hospital, Sydney, New South Wales, Australia., Petoumenos K; Australian HIV Observational Database (AHOD), UNSW, Sydney, New South Wales, Australia., Borgans F; Department of Internal Medicine, Infectious Diseases, Frankfurt HIV Cohort Study, Goethe-University Hospital, University Hospital, Frankfurt, Germany., Bonnet F; Bordeaux Population Health Centre & CHU de Bordeaux, University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Saint-André Hospital, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, Cedex, France., De Wit S; Department of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium., El-Sadr W; Mailman School of Public Health, Columbia University, New York, New York, USA., Neesgaard B; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Jaschinski N; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Greenberg L; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Hosein SR; European AIDS Treatment Group (EATG), Brussels, Belgium., Gallant J; Gilead Sciences, Foster City, California, USA., Vannappagari V; ViiV Healthcare, Research Triangle Park, North Carolina, USA., Young L; Merck Sharp & Dohme, Rahway, New Jersey, USA., Sabin C; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom., Lundgren J; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Peters L; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Reekie J; Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Nov 22; Vol. 79 (5), pp. 1242-1257.

Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study.

Autor: Oomen PGA; Department of Infectious Diseases, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: p.g.a.oomen-2@umcutrecht.nl., Wit FWNM; Stichting HIV Monitoring, Amsterdam, Netherlands; Amsterdam UMC, Location University of Amsterdam, Department of Infectious Diseases, Amsterdam, Netherlands; Amsterdam Institute for Immunology & Infectious diseases, Infectious Diseases Program, Amsterdam, Netherlands., Brinkman K; Department of Internal Medicine and Infectious Diseases, OLVG, Amsterdam, Netherlands., Vrouenraets SME; Department of Internal Medicine and Infectious Diseases, OLVG, Amsterdam, Netherlands., Mudrikova T; Department of Infectious Diseases, University Medical Center Utrecht, Utrecht, Netherlands., van Welzen BJ; Department of Infectious Diseases, University Medical Center Utrecht, Utrecht, Netherlands., van der Valk M; Stichting HIV Monitoring, Amsterdam, Netherlands; Amsterdam UMC, Location University of Amsterdam, Department of Infectious Diseases, Amsterdam, Netherlands; Amsterdam Institute for Immunology & Infectious diseases, Infectious Diseases Program, Amsterdam, Netherlands.

Publikováno v: The lancet. HIV [Lancet HIV] 2024 Sep; Vol. 11 (9), pp. e576-e585.

Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study.

Autor: Hatleberg, Camilla I.¹ camilla.hatleberg@regionh.dk, Ryom, Lene¹, El‐Sadr, Wafaa², Mocroft, Amanda³, Reiss, Peter⁴, De Wit, Stephane⁵, Dabis, Francois⁶, Pradier, Christian⁷, d'Arminio Monforte, Antonella⁸, Kovari, Helen⁹, Law, Matthew¹⁰, Lundgren, Jens D.¹, Sabin, Caroline A.³, the Data Collection of Adverse Events of Anti‐HIV drugs (D:A:D) Study group

Publikováno v: Journal of the International AIDS Society. Mar2018, Vol. 21 Issue 3, p1-1. 13p. 3 Charts, 2 Graphs.